PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival

Bibliographic Details
Title: PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival
Authors: Shaochuan Liu, Tingting Qin, Yanan Jia, Kai Li
Source: Frontiers in Oncology, Vol 9 (2019)
Publisher Information: Frontiers Media S.A., 2019.
Publication Year: 2019
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: PD-L1, VEGFA, overall survival, progression-free survival, lung adenocarcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Objectives: To elucidate the relationship between VEGFA and PD-L1 expression in lung adenocarcinoma (LADC).Methods: PD-L1 and VEGFA expression were determined by immunohistochemistry with H-score on formalin-fixed paraffin-embedded resected LADC specimens of 129 cases.Results: High PD-L1 expression in 53 (41.1%) patients, high VEGFA expression in 65 (50.4%), and co-expression in 18 (14.0%) were observed. Inverse correlation between expression of PD-L1 and VEGFA was found (P = 0.002, r = −0.274). VEGFA and PD-L1 expression were not significantly associated with the clinicopathological features. High PD-L1 expression was significantly association with all patients' poor progression-free survival and overall survival in a univariate analysis, but there was no significantly association with high VEGFA expression and prognosis. Co-expression of PD-L1 and VEGFA exhibited a worst overall survival compared to negative groups (P = 0.005).Conclusions: These findings indicate that high PD-L1 expression could impact both poor overall survival and progression-free survival in patients with resected LADC. Co-expression of PD-L1 and VEGFA may be considered as an important prognostic factor for patients with resected lung adenocarcinoma.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/article/10.3389/fonc.2019.00189/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2019.00189
Access URL: https://doaj.org/article/d9c823252a2249e4ba599f4ddede8285
Accession Number: edsdoj.9c823252a2249e4ba599f4ddede8285
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2019.00189
Published in:Frontiers in Oncology
Language:English